294 related articles for article (PubMed ID: 27448759)
1. Dual Targeting of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase and Histone Deacetylase as a Therapy for Colorectal Cancer.
Wei TT; Lin YT; Chen WS; Luo P; Lin YC; Shun CT; Lin YH; Chen JB; Chen NW; Fang JM; Wu MS; Yang KC; Chang LC; Tai KY; Liang JT; Chen CC
EBioMedicine; 2016 Aug; 10():124-36. PubMed ID: 27448759
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of dual-action inhibitors targeting histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme A reductase for cancer treatment.
Chen JB; Chern TR; Wei TT; Chen CC; Lin JH; Fang JM
J Med Chem; 2013 May; 56(9):3645-55. PubMed ID: 23570542
[TBL] [Abstract][Full Text] [Related]
3. Prevention of Colitis and Colitis-Associated Colorectal Cancer by a Novel Polypharmacological Histone Deacetylase Inhibitor.
Wei TT; Lin YT; Tseng RY; Shun CT; Lin YC; Wu MS; Fang JM; Chen CC
Clin Cancer Res; 2016 Aug; 22(16):4158-69. PubMed ID: 27528734
[TBL] [Abstract][Full Text] [Related]
4. Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer.
Lipkin SM; Chao EC; Moreno V; Rozek LS; Rennert H; Pinchev M; Dizon D; Rennert G; Kopelovich L; Gruber SB
Cancer Prev Res (Phila); 2010 May; 3(5):597-603. PubMed ID: 20403997
[TBL] [Abstract][Full Text] [Related]
5. Inhibiting HDAC1 Enhances the Anti-Cancer Effects of Statins through Downregulation of GGTase-Iβ Expression.
Li R; Gan YH
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28481295
[TBL] [Abstract][Full Text] [Related]
6. The 3-hydroxy-3-methylglutaryl coenzyme-A reductases from fungi: a proposal as a therapeutic target and as a study model.
Andrade-Pavón D; Sánchez-Sandoval E; Rosales-Acosta B; Ibarra JA; Tamariz J; Hernández-Rodríguez C; Villa-Tanaca L
Rev Iberoam Micol; 2014; 31(1):81-5. PubMed ID: 24270073
[TBL] [Abstract][Full Text] [Related]
7. A dual inhibitor targeting HMG-CoA reductase and histone deacetylase mitigates neurite degeneration in
Lin CH; Lin HY; Fang JM; Chen CC
Aging (Albany NY); 2020 Nov; 12(24):25581-25598. PubMed ID: 33231564
[TBL] [Abstract][Full Text] [Related]
8. The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway.
Kodach LL; Bleuming SA; Peppelenbosch MP; Hommes DW; van den Brink GR; Hardwick JC
Gastroenterology; 2007 Oct; 133(4):1272-81. PubMed ID: 17919499
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms underlying the antitumor activity of (E)-N-hydroxy-3-(1-(4-methoxyphenylsulfonyl)-1,2,3,4-tetrahydroquinolin-6-yl)acrylamide in human colorectal cancer cells in vitro and in vivo.
Chen CH; Lee CH; Liou JP; Teng CM; Pan SL
Oncotarget; 2015 Nov; 6(34):35991-6002. PubMed ID: 26462017
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitors induce attenuation of Wnt signaling and TCF7L2 depletion in colorectal carcinoma cells.
Götze S; Coersmeyer M; Müller O; Sievers S
Int J Oncol; 2014 Oct; 45(4):1715-23. PubMed ID: 25050608
[TBL] [Abstract][Full Text] [Related]
11. Exploring Leishmania donovani 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) as a potential drug target by biochemical, biophysical and inhibition studies.
Dinesh N; Pallerla DS; Kaur PK; Kishore Babu N; Singh S
Microb Pathog; 2014 Jan; 66():14-23. PubMed ID: 24239940
[TBL] [Abstract][Full Text] [Related]
12. Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2.
Lin YC; Lin JH; Chou CW; Chang YF; Yeh SH; Chen CC
Cancer Res; 2008 Apr; 68(7):2375-83. PubMed ID: 18381445
[TBL] [Abstract][Full Text] [Related]
13. Novel β-Carboline/Hydroxamic Acid Hybrids Targeting Both Histone Deacetylase and DNA Display High Anticancer Activity via Regulation of the p53 Signaling Pathway.
Ling Y; Xu C; Luo L; Cao J; Feng J; Xue Y; Zhu Q; Ju C; Li F; Zhang Y; Zhang Y; Ling X
J Med Chem; 2015 Dec; 58(23):9214-27. PubMed ID: 26555243
[TBL] [Abstract][Full Text] [Related]
14. TACC3 overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors.
He JC; Yao W; Wang JM; Schemmer P; Yang Y; Liu Y; Qian YW; Qi WP; Zhang J; Shen Q; Yang T
Oncotarget; 2016 Nov; 7(46):75441-75456. PubMed ID: 27705912
[TBL] [Abstract][Full Text] [Related]
15. Structural mechanism for statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase.
Istvan ES
Am Heart J; 2002 Dec; 144(6 Suppl):S27-32. PubMed ID: 12486413
[TBL] [Abstract][Full Text] [Related]
16. Histone Deacetylases and their Inhibitors in Colorectal Cancer Therapy: Current Evidence and Future Considerations.
Garmpis N; Damaskos C; Garmpi A; Nonni A; Georgakopoulou VE; Antoniou E; Schizas D; Sarantis P; Patsouras A; Syllaios A; Vallilas C; Koustas E; Kontzoglou K; Trakas N; Dimitroulis D
Curr Med Chem; 2022; 29(17):2979-2994. PubMed ID: 34525905
[TBL] [Abstract][Full Text] [Related]
17. Is there a relationship between 3-hydroxy-3-methylglutaryl coenzyme a reductase activity and forebrain pathology in the PKU mouse?
Shefer S; Tint GS; Jean-Guillaume D; Daikhin E; Kendler A; Nguyen LB; Yudkoff M; Dyer CA
J Neurosci Res; 2000 Sep; 61(5):549-63. PubMed ID: 10956425
[TBL] [Abstract][Full Text] [Related]
18. Structural mechanism for statin inhibition of HMG-CoA reductase.
Istvan ES; Deisenhofer J
Science; 2001 May; 292(5519):1160-4. PubMed ID: 11349148
[TBL] [Abstract][Full Text] [Related]
19. Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells.
Zhijun H; Shusheng W; Han M; Jianping L; Li-Sen Q; Dechun L
Tumour Biol; 2016 Aug; 37(8):10257-67. PubMed ID: 26831668
[TBL] [Abstract][Full Text] [Related]
20. Could drugs inhibiting the mevalonate pathway also target cancer stem cells?
Likus W; Siemianowicz K; Bieńk K; Pakuła M; Pathak H; Dutta C; Wang Q; Shojaei S; Assaraf YG; Ghavami S; Cieślar-Pobuda A; Łos MJ
Drug Resist Updat; 2016 Mar; 25():13-25. PubMed ID: 27155373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
